Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Learn Why The Bull Case For Intuitive Surgical Stock Could Change Following Earnings Report

Earnings report AI-generated analysis

πŸ“… Intuitive Surgical is scheduled to report earnings after market close on October 20, 2026.

πŸ“‰ Analyst expectations for revenue growth have moderated to 15.6% year-over-year compared to 22.9% in the same quarter last year.

πŸ’° Consensus forecasts project revenue growing at 11.9% annually over the next three years with profit margins expanding from 28.4% to 30.7%.

πŸš€ Long-term models anticipate earnings reaching US$4.8 billion by 2029, up from US$3.1 billion today.

⚠️ A cautious analyst set projects lower long-term earnings of US$4.2 billion by 2029 with only a small lift in profit margins.

πŸ” Key operational metrics to watch include procedure growth on da Vinci and Ion systems and the mix between new placements versus leasing.

πŸ›‘οΈ The company maintains a debt-free balance sheet while facing potential risks from competitive noise and pricing pressure on recurring revenue.

πŸ“Š Analyst models assume shares outstanding will edge down by about 0.34% annually over the next three years, potentially lifting earnings per share.

Bullish Signals
  • Intuitive Surgical maintains a debt-free balance sheet, providing financial flexibility to navigate market changes and invest in growth.
  • Analysts project profit margins will expand from 28.4% today to 30.7% by year three as the fleet grows and digital offerings scale.
  • The company's recurring revenue narrative is supported by increasing utilization of installed da Vinci and Ion robotic systems globally.
  • Consensus long-term forecasts indicate a significant earnings increase of roughly US$1.7 billion, growing from US$3.1b today to US$4.8b by 2029.
Risk Factors
  • Revenue growth expectations have moderated significantly to 15.6% year-over-year, down from a faster clip of 22.9% in the same quarter last year.
  • Risks include potential softening of system placements in pressured regions such as China or parts of Europe.
  • The short-term story could feel fragile if early competitive noise from new soft tissue robotics platforms picks up momentum.
  • Investors are watching for any visible pricing or margin pressure on high-margin recurring instruments and service revenue.
Full Analysis
Intuitive Surgical (ISRG) is preparing to report quarterly earnings after market close on October 20, 2026. Analyst expectations for revenue growth have moderated to 15.6% year-over-year, down from 22.9% in the prior year's quarter, though forecasts remain largely unchanged heading into the release. The market is closely watching how the company's leadership in robotic surgery and its debt-free balance sheet navigate these moderating top-line expectations as the installed base and procedure mix evolve. The investment narrative for Intuitive Surgical centers on recurring revenue streams derived from its da Vinci and Ion robotic systems. Analyst models project that revenue will grow at an 11.9% annual rate over the next three years, with profit margins expected to expand from 28.4% today to 30.7% by year three. This growth is driven by increased utilization of existing systems and a richer earnings mix as digital offerings scale alongside the growing fleet of surgical robots. Long-term consensus forecasts suggest Intuitive Surgical could reach US$15.5 billion in revenue and US$4.8 billion in earnings by 2029, representing an increase of roughly US$1.7 billion from current levels. However, a more cautious analyst set projects lower figures of US$14.6 billion in revenue and US$4.2 billion in earnings by the same date. Key operational signals investors will scrutinize include procedure growth rates, the mix between new system placements versus leasing, and any commentary regarding competition or pricing pressure on high-margin recurring instruments.